Peptide T

Drug Profile

Peptide T

Latest Information Update: 21 Aug 2007

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Karolinska Institute; National Institutes of Health (USA)
  • Developer Advanced Immuni T
  • Class Anti-inflammatories; Antipsoriatics; Antivirals; Peptides
  • Mechanism of Action CCR5 receptor antagonists; Immunomodulators; Tumour necrosis factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Alzheimer's disease; Cachexia; Chronic fatigue syndrome; Herpesvirus infections; HIV infections; Inflammatory bowel diseases; Multiple sclerosis; Polyomavirus infections; Psoriasis; Rheumatoid arthritis

Most Recent Events

  • 20 Aug 2004 Peptide T is available for licensing worldwide(
  • 20 Aug 2004 Phase-I/II clinical trials in Alzheimer's disease in Canada (Intranasal)
  • 20 Aug 2004 Phase-I/II clinical trials in Chronic fatigue syndrome in Canada (Intranasal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top